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ERT impact on left ventricular mass in Fabry disease
To the Editor,
We read with interest the systematic review on clinical outcomes in
Fabry males [1]. However, two statements did not fully represent the
results of the original publication cited: “One of these noted a statisti-
cally signiﬁcant decrease from baseline in LVM with ERT in patients
without ﬁbrosis, but no such eﬀect in patients with mild or severe ﬁ-
brosis [174]” and “the importance of administering ERT early was
demonstrated in patients without ﬁbrosis at baseline. They experienced
a statistically signiﬁcant decline from baseline in LVM and a statistically
signiﬁcant improvement in exercise capacity with ERT, while patients
in whom treatment was started when mild or severe ﬁbrosis was al-
ready present experienced no eﬀect of ERT [174].” Both refer to table 3
of Weidemann et al., which is not easy to interpret since the meaning of
the p values diﬀers for the diﬀerent lines of the table [2]. Thus, in the no
ﬁbrosis group, LV mass decreased from 238 ± 42 to 202 ± 46 g and
this mean decrease of 36 g was statistically signiﬁcant (p < .01), as
correctly reported by Germain et al. However, in mild ﬁbrosis, the LV
mass decreased from 275 ± 62 to 244 ± 65 and this 31 g decrease did
not diﬀer from the decrease observed in the no ﬁbrosis group (p 0.31 vs
changes observed in the no ﬁbrosis group), similar to the observation in
the severe ﬁbrosis group (LV decreased from 303 ± 84 to 247 ± 45 g,
a mean decrease of 56 g that did not diﬀer from the decrease observed
in the no ﬁbrosis group (p 0.24 vs changes observed in the no ﬁbrosis
group). Thus, a signiﬁcant decrease in LV mass was observed in patients
with no ﬁbrosis and the decrease in LV mass observed in patients with
ﬁbrosis did not signiﬁcantly diﬀer from the decrease observed in pa-
tients with no ﬁbrosis.
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